Passive antibody therapy in COVID-19

Jonathan Abraham

doi:10.1038/s41577-020-0365-7

Passive antibody therapy in COVID-19

Nat Rev Immunol. 2020 Jul;20(7):401-403. doi: 10.1038/s41577-020-0365-7.

Author

Jonathan Abraham^{1

2

3

4}

Affiliations

¹ Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. jonathan_abraham@hms.harvard.edu.
² Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. jonathan_abraham@hms.harvard.edu.
³ Broad Institute of Harvard and MIT, Cambridge, MA, USA. jonathan_abraham@hms.harvard.edu.
⁴ Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA. jonathan_abraham@hms.harvard.edu.

Abstract

For over a century, transfusion of convalescent plasma from recovered individuals has been tried as a therapeutic approach when a novel pathogen emerges. As the world awaits SARS-CoV-2 vaccines to be tested and safely deployed, the rapidity with which antiviral monoclonal antibodies can be isolated and engineered offers an attractive alternative option for passive immunization.

MeSH terms

Animals
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / immunology
Antibodies, Neutralizing / immunology
Antibodies, Viral / administration & dosage
Antibodies, Viral / immunology
Betacoronavirus
COVID-19
COVID-19 Serotherapy
Coronavirus Infections / immunology*
Coronavirus Infections / therapy*
Humans
Immunization, Passive
Pandemics
Pneumonia, Viral / immunology*
Pneumonia, Viral / therapy*
SARS-CoV-2
Spike Glycoprotein, Coronavirus / immunology

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2